Novo Nordisk (NYSE:NVO) has filed litigation in a Delaware district court against Mylan N.V. (NASDAQ:MYL) aimed at blocking its attempt to market a generic version of top seller Victoza (liraglutide). The seven patents being challenged expire in 2021 – 2033.
The lawsuit triggers an automatic 30-month stay on FDA approval so there is a long road ahead.
The GLP-1 receptor agonist accounted for almost 25% of the company’s Q2 U.S. sales and over 11% of its global sales.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.